SRR5088899
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- ANGIOGENESIS+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- COAGULATION+0.400
- INFLAMMATORY_RESPONSE+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ALLOGRAFT_REJECTION+0.300
- APICAL_JUNCTION+0.300
- APICAL_SURFACE+0.300
- COMPLEMENT+0.300
Top 10 suppressed
- PROTEIN_SECRETION-0.400
- MYC_TARGETS_V1-0.300
- OXIDATIVE_PHOSPHORYLATION-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- UV_RESPONSE_DN-0.200
- BILE_ACID_METABOLISM-0.100
- FATTY_ACID_METABOLISM-0.100
- INTERFERON_ALPHA_RESPONSE-0.100
- TGF_BETA_SIGNALING-0.100
- ADIPOGENESIS+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.899 |
| 2 | b556b718-38cf-498d-94c7-4e240fe57d48 | — | — | 0.859 |
| 3 | 718de66e-06d2-4c2c-8b2d-e40087c4340c | — | — | 0.840 |
| 4 | 82992 | EPN | Supratentorial EPN | 0.810 |
| 5 | BS_0QYS36NR | Ependymoma NOS | — | 0.810 |
| 6 | BS_QWTE1CWR | high-grade glioma | — | 0.796 |
| 7 | C3L-02951 | — | cohortSQ1 | 0.792 |
| 8 | SRR2778056 | — | — | 0.789 |
| 9 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.786 |
| 10 | 06c948c5-b714-40b8-b4ce-814effef62c7 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |